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Abstract—A series of imidazolopyrazinones 3, substituted at C-2, and C-2/C-6, has been prepared. The compounds behaved as
quenchers of superoxide anion. The more active compounds are structurally related to coelenterazine, a natural substrate of marine
bioluminescence. Theoretical parameters based on Hartree–Fock instabilities have been examined.# 2001 Elsevier Science Ltd. All
rights reserved.
Partially reduced derivatives of oxygen, which are pro-
duced in aerobic organisms as part of normal physio-
logical and metabolic processes, are toxic species since
they can oxidize numerous biomolecules leading to tis-
sue injury and cell death.1 Such reactive oxygen species
(ROS), produced in excessive concentrations or in
wrong locations, cause an oxidative stress associated
with a variety of disease states in humans.24 Thus,
when the natural protective systems towards ROS is
running over, exogeneous antioxidative compounds
have to be delivered. The research of new antioxidants
as potential drugs is an active ﬁeld of medicinal
chemistry.57 The compounds usually involve N-hetero-
cycle and/or phenol moieties as radical scavengers.
Recently, we demonstrated that coelenterazine (CLZ;
Scheme 1, Table 1) shows high antioxidative properties
in cells submitted to oxidative stress induced by t-butyl
hydroperoxide, and inhibits the oxidation of linoleate
initiated by azoperoxyl radicals.810 Coelenterazine is an
imidazolopyrazinone derivative isolated from marine
organisms; this natural compound is the chromophoric
ligand of a calcium-sensitive photoprotein called
aequorin.1113 The molecular mechanism of CLZ biolu-
minescence and chemiluminescence is still a subject of
investigations:14,15 the catalyzed oxidation of CLZ
produces carbon dioxide and coelenteramide in an exci-
ted state which deactivates by emission of light.
The sensitivity of CLZ towards oxygen and ROS led us
to consider this heterocyclic system as a potential lead in
medicinal chemistry for the discovery of new anti-
oxidants.16 In this paper, a series of simple imidazolo-
pyrazinones, structurally related to CLZ, has been
prepared and evaluated in a standard test towards
superoxide anion, in view to assess the interest of this
class of compounds. Theoretical evaluation also sug-
gested a high antioxidative potential for imidazolopyr-
azinone compounds.
Imidazolopyrazinones 3a–l (Scheme 1, Table 1) were
readily obtained by condensing 2-aminopyrazines 1 with
a-keto-aldehydes (or the derived acetals) 2, according to
known procedures.1620 5-Aryl-2-aminopyrazines (R16¼H)
resulted from a Suzuki-like coupling21 of 5-bromo-2-
aminopyrazine22 with arylboronic acids (phenylboronic
acid and 4-methoxyphenylboronic acid). The depro-
tection of 5-(4-methoxyphenyl)-2-aminopyrazine into
5-(4-hydroxyphenyl)-2-aminopyrazine was realized with
sodium ethanethiolate in DMF at 100 C.23 The diethyl
acetal of benzyl glyoxal (R3=PhCH2) was prepared by
substitution of 1-(diethoxyacetyl) piperidine with benzyl-
magnesium bromide.24
Compounds 3, isolated as the hydrochloride salts,25
were characterized by NMR spectroscopy. Since no
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complete data for imidazolopyrazinones26 have been
found in literature, we collected the spectroscopic values
of 3a–l in Tables 2 and 3 (spectra recorded respectively
at 500 and 125MHz). Typically, in the 1H spectra
(Table 2), H-5 appeared at 8.2–8.5 d when R3 is an alkyl
group (R3=CH3, CH2Ph), and at 7.8–8.1 d when R3 is
phenyl. Similarly, H-8 was slightly shielded when R3 is
phenyl (8.3–8.5 d) comparatively to the chemical shift
found for this proton when R3 is an alkyl group (8.6–8.9
d). The 13C spectra (Table 3) showed the signal attrib-
uted to the carbonyl function (C-3) around 148 d when
R3 is phenyl, and at 136–142 d when R3 is an alkyl
group (R3=CH3, CH2Ph). This is consistent with pre-
vious data obtained by X-ray diﬀraction analysis of
crystals:16 2-phenylimidazolopyrazinone 3b appeared in
the ketone form, while 2-methylimidazolopyrazinone 3a
was stabilized in the enol tautomeric form. In structures
3d–l, the chemical shifts of C-2 and C-9, two atoms
making part of the conjugated system which extends
from N-7 to C-3,16 are very similar. On the other hand,
C-6 and C-8 appear to be inﬂuenced by the nature (aryl
or alkyl) of the substituent R3.
The chemical reactivity of CLZ towards ROS has been
correlated to the rate constant of its reaction with
superoxide anion using the hypoxanthine–xanthine
oxidase system.27,28 The same test was used for the eva-
luation of the synthetic imidazolopyrazinones in the
presence of MeO–CLZ (Scheme 1, Table 1) as the com-
petitor. The rate constant of this luminescent reference16
has been previously determined by using TroloxR, a
water-soluble derivative of vitamin E,29 as the known
competitor (Table 4). Thus, compounds 3a–l were reac-
ted with O2
 in the presence of MeO–CLZ in diﬀerent
concentrations;30 the intensities of light emission were
measured at 380 nm, and the reaction rate constants
were calculated from the following equation:3133
Io=Ic ¼ 1þ kc=ki  ½MeOCLZ=½3
where Io=luminescence measured without MeO–CLZ,
Ic=luminescence measured in the presence of MeO–
CLZ (competitor), kc=rate constant of MeO–CLZ
(competitor), ki=rate constant of the tested compound
3, [MeO–CLZ]=concentration of competitor and
[3]=concentration of tested compound.
Table 1. Imidazolopyrazinone derivatives
Compd R1 R2 R3 Ref
CLZ p-HO-Ph CH2Ph CH2-Ph-p-OH 17–19
MeO–CLZ p-MeO-Ph CH2Ph CH2-Ph-p-OH 8,10
3a H H Me 16
3b H H Ph 16
3c H H CH2Ph 20
3d Ph H Me 20
3e Ph H Ph 20
3f Ph H CH2Ph 20
3g p-MeO-Ph H Me 20
3h p-MeO-Ph H Ph 20
3i p-MeO-Ph H CH2Ph 20
3j p-HO-Ph H Me 20
3k p-HO-Ph H Ph 20
3l p-HO-Ph H CH2Ph 20
Table 2. 1H NMR data (d)
Compd Solvent H-5 H-6 H-8 J (Hz)
3a CD3OD 8.09 7.65 8.78
3J56=5.5; 5J58=1.1
DMSO-d6 8.30 7.73 8.99
4J68=0.5
3b CD3OD 8.29 7.70 8.86
3J56=5.5; 5J58=0.8
DMSO-d6 7.87 7.22 8.47
4J68=0.5
3c CD3OD 8.19 7.70 8.77
3J56=5.5; 5J58=0.9
4J68=0.5
3d CD3OD 8.30 — 8.76
5J58=1.1
3e DMSO-d6 8.15 — 8.44
3f CD3OD 8.24 — 8.61
5J58=0.8
3g CD3OD 8.41 — 8.88
5J58=1.1
3h DMSO-d6 7.89 — 8.30
3i CD3OD 8.57 — 8.96
5J58=0.9
3j DMSO-d6 8.48 — 8.90
3k DMSO-d6 7.88 — 8.33
3l CD3OD 8.42 — 8.84
5J58=0.9
Scheme 1.
Table 3. 13C NMR data (d)
Compd Solvent C-2 C-3 C-5 C-6 C-8 C-9
3a CD3OD 135.9 142.8 116.5 122.4 133.6 130.3
DMSO-d6 137.4 142.9 114.4 119.1 130.1 128.8
3b CD3OD 139.0 148.2 113.4 116.1 127.1 129.0
DMSO-d6 139.4 149.9 112.5 115.5 125.7 129.1
3c CD3OD 140.3 144.5 116.2 121.2 132.6 130.7
3d CD3OD 123.9 139.9 112.4 141.2 135.8 128.5
3e DMSO-d6 128.7 148.0 109.5 129.2 128.0 129.3
3f CD3OD 124.3 141.4 112.5 141.2 134.8 129.3
3g CD3OD 126.9 140.0 111.2 141.0 134.7 128.8
3h DMSO-d6 128.7 148.7 108.3 129.5 127.2 129.3
3i CD3OD 126.2 140.5 111.4 141.0 133.4 129.0
3j DMSO-d6 127.0 137.5 109.6 139.2 133.6 127.0
3k DMSO-d6 128.6 147.8 108.1 129.2 127.6 129.3
3l CD3OD 127.4 136.5 110.7 141.4 135.0 129.5
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The results, summarized in Table 4, clearly showed that
all the tested imidazolopyrazinones are more active than
TroloxR; however, two compounds (3e and 3h) could
not be evaluated because they were not totally soluble in
the required concentrations. The presence of an aryl
substituent R1 at position C-6 increased the activity,
comparatively to the C-6 unsubstituted series (com-
pounds 3d, 3g, and 3j). The substituent R3 at position
C-2 appeared to exercise a moderate inﬂuence. Accord-
ingly, the p-hydroxybenzyl substituent found in the
natural CLZ is not absolutely required. Compared to
the natural derivatives (CLZ and MeO–CLZ) possess-
ing a benzyl substituent (R2) at position C-8, the
synthetic derivatives 3 devoid of such a substitution are
2 or 3 times more active. Thus, simple imidazolopyr-
azinones, more easily synthesized than CLZ, can be
considered as potential antioxidants.
Theoretical parameters have been recently deﬁned to
characterize antioxidants and to predict antioxidative
activities. Testa et al.34,35 considered 
Hox (relative
adiabatic oxidation potential) and the shape of the
SOMO (singly occupied molecular orbital) as the quan-
tum chemical descriptors. More recently, Haemers et
al.36 correlated antioxidant activity with radical stabili-
zation properties. These parameters are derived from
the analysis of the radical form obtained by elimination
of one electron. In the present study, an analysis of the
propension of the neutral compounds 3 with all their
paired electrons to generate radicalar structures is con-
cerned. This approach is based on the investigation of
Hartree–Fock instabilities. By its fused ﬁve-membered
ring, the imidazolopyrazinone compounds break down
the aromaticity and only one Kekule´ form can be
drawn. This feature has been previously pointed out as
a source of the wave function instability.37 It is related
to the vicinity of a triplet electronic state near the fun-
damental singlet state. Imidazole wave function is stable
and that of pyrazine presents the same weak instability
as benzene and pyridine; but the association of the two
fragments leads to a signiﬁcant instability. This one can
be seen as a propensity of the molecules to present a
local biradicalar character which could directly be rela-
ted to their reactivity towards superoxide anion.
The Hartree–Fock instabilities38 of compounds 3 are
summarized in Table 5. At the singlet state structure,
the optimization of the wave function gives rise to a
stabilization energy (delta-stable). From this result, a
complete geometry re-optimization generates the rela-
tive energy values at the UHF level (UHF/UHF) in
which alpha and beta electrons occupy diﬀerent spatial
molecular orbitals. The more the molecule is substituted
by aromatic fragments, the more the stabilization
energy is high. This feature is nicely correlated to the
antioxidant activity for the four compounds bearing a
methyl substituent at position C-2 (R3=CH3), namely
3a, 3d, 3j, and 3g. With a benzyl substituent in that
position (R3=CH2–Ph), additional steric eﬀects could
explain the less clear relation with activity, except
between 3c and 3i. Figure 1 shows the spin density of
the reference compound 3 (R1=R2=R3=H): the iso-
contour of spin density at 0.005 AU (e/A**3) displays
the alternation of positive and negative clouds. The
break induced by the substitution is illustrated with
compound 3j (Fig. 1).39 For both molecules, the highest
spin density is located on the carbon atoms C-2 and C-8.
Thus, imidazolopyrazinones represent a valuable class
of new antioxidants; an aryl substituent R1 at position
Table 5. Theoretical parameters
Compd Delta-E stable Delta-E UHF/UHF Stabilization
3a 16.29 27.89 11.60
3b 31.18 46.48 15.30
3c 25.00 39.72 14.72
3d 28.37 44.01 15.64
3f 36.96 54.75 17.79
3g 27.35 42.78 15.43
3i 35.60 53.92 18.32
3j 27.42 42.87 15.45
3l 35.52 52.87 17.35
Referencea 17.59 30.36 12.77
aReference=compd 3 with R1=R2=R3=H.
Table 4. Reaction rate constants with O2
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I. Devillers et al. / Bioorg. Med. Chem. Lett. 11 (2001) 2305–2309 2307
C-6, in particular a phenol moiety, reinforces this prop-
erty, while the R3 substituent at position C-2 seems to
play a moderate role. The C-8 position, substituted with
a benzyl group (R2=Bz) in the natural CLZ but
unsubstituted in the synthetic derivatives 3a–l
(R2=H), could be used for the anchorage of mole-
cular fragments susceptible to improve the biodis-
ponibility.
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